Furthermore, our data shed light on a potential mechanism involving NLRP2 overexpression in the pathogenesis of cystinosis and other tubulopathies, providing the rationale for novel targeted anti-inflammatory therapeutic strategies that may complement presently available conventional therapies. This evidence concerns the gene NLRP2 and cystinosis.